IL163902A0 - Antibodies against cancer antigen tmeff2 and uses thereof - Google Patents

Antibodies against cancer antigen tmeff2 and uses thereof

Info

Publication number
IL163902A0
IL163902A0 IL16390203A IL16390203A IL163902A0 IL 163902 A0 IL163902 A0 IL 163902A0 IL 16390203 A IL16390203 A IL 16390203A IL 16390203 A IL16390203 A IL 16390203A IL 163902 A0 IL163902 A0 IL 163902A0
Authority
IL
Israel
Prior art keywords
antibodies against
cancer antigen
against cancer
tmeff2
antigen tmeff2
Prior art date
Application number
IL16390203A
Other languages
English (en)
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of IL163902A0 publication Critical patent/IL163902A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL16390203A 2002-03-08 2003-03-07 Antibodies against cancer antigen tmeff2 and uses thereof IL163902A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36283702P 2002-03-08 2002-03-08
US43681202P 2002-12-27 2002-12-27
PCT/US2003/007209 WO2003075855A2 (fr) 2002-03-08 2003-03-07 Anticorps diriges contre l'antigene cancereux tmeff2 et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
IL163902A0 true IL163902A0 (en) 2005-12-18

Family

ID=27807977

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16390203A IL163902A0 (en) 2002-03-08 2003-03-07 Antibodies against cancer antigen tmeff2 and uses thereof

Country Status (15)

Country Link
US (5) US7288248B2 (fr)
EP (1) EP1572087B1 (fr)
JP (2) JP2006502092A (fr)
KR (1) KR101104655B1 (fr)
AT (1) ATE395082T1 (fr)
AU (1) AU2003252830B2 (fr)
CA (1) CA2478683C (fr)
DE (1) DE60321041D1 (fr)
DK (1) DK1572087T3 (fr)
ES (1) ES2305481T3 (fr)
IL (1) IL163902A0 (fr)
PT (1) PT1572087E (fr)
SI (1) SI1572087T1 (fr)
WO (1) WO2003075855A2 (fr)
ZA (1) ZA200407733B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506908A (ja) * 1995-05-19 1999-06-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド トランスフォーミング増殖因子αHII
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
CA2478683C (fr) * 2002-03-08 2016-01-26 Protein Design Labs, Inc. Anticorps diriges contre l'antigene cancereux tmeff2 et utilisations de ceux-ci
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2004067564A2 (fr) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions contre l'antgene cancereux liv-1 et leurs utilisations
EP2478912B1 (fr) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Conjugués d'auristatin avec des anticorps dirigés contre le HER2 ou le CD22 et leur usage thérapeutique
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
NZ579482A (en) * 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
EP1907001B1 (fr) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Molecules de liaison ilt3 et leurs utilisations
WO2007002525A2 (fr) * 2005-06-28 2007-01-04 Schering Aktiengesellschaft Anticorps de tomoreguline et leurs utilisations
CA2655903A1 (fr) * 2006-06-19 2008-08-07 Tolerx, Inc. Molecules se liant a l'ilt3 et leurs utilisations
US20100285335A1 (en) * 2007-02-05 2010-11-11 Humphrey Samkelo Lungisani Sithebe Polycrystalline diamond (pcd) materials
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
EP2176295B1 (fr) 2007-07-16 2014-11-19 Genentech, Inc. Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
NZ584514A (en) * 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-cd79b 항체 및 면역접합체 및 사용 방법
EP2634268A3 (fr) * 2009-01-07 2013-12-25 QuantiBact A/S Enrichissement et identification de cellules foetales dans le sang maternel et ligands pour une telle utilisation
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
EP2648752B1 (fr) 2010-12-06 2017-02-15 Seattle Genetics, Inc. Anticorps humanisés dirigés vers liv-1 et leur utilisation pour traiter le cancer
WO2013093122A2 (fr) * 2011-12-23 2013-06-27 Phenoquest Ag Anticorps pour le traitement et le diagnostic de troubles affectifs et de l'anxiété
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
MX2018010847A (es) 2016-03-15 2019-07-04 Seattle Genetics Inc Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
SG11202113242QA (en) 2019-06-07 2021-12-30 Arcedi Biotech Aps Isolation of fetal cells using facs
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク,インコーポレーテツド カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478683C (fr) 2002-03-08 2016-01-26 Protein Design Labs, Inc. Anticorps diriges contre l'antigene cancereux tmeff2 et utilisations de ceux-ci

Also Published As

Publication number Publication date
AU2003252830B2 (en) 2008-10-09
US7824678B2 (en) 2010-11-02
US20080160012A1 (en) 2008-07-03
EP1572087A4 (fr) 2006-11-02
JP5192537B2 (ja) 2013-05-08
US20080044840A1 (en) 2008-02-21
US7288248B2 (en) 2007-10-30
US20110038864A1 (en) 2011-02-17
ATE395082T1 (de) 2008-05-15
US8257708B2 (en) 2012-09-04
EP1572087A2 (fr) 2005-09-14
CA2478683A1 (fr) 2003-09-18
EP1572087B1 (fr) 2008-05-14
JP2006502092A (ja) 2006-01-19
US7674883B2 (en) 2010-03-09
JP2011121950A (ja) 2011-06-23
KR20050002848A (ko) 2005-01-10
WO2003075855A3 (fr) 2006-03-23
KR101104655B1 (ko) 2012-01-13
PT1572087E (pt) 2008-07-11
US20040096392A1 (en) 2004-05-20
WO2003075855A2 (fr) 2003-09-18
DE60321041D1 (de) 2008-06-26
US20080175846A1 (en) 2008-07-24
ES2305481T3 (es) 2008-11-01
CA2478683C (fr) 2016-01-26
US7785816B2 (en) 2010-08-31
SI1572087T1 (sl) 2008-10-31
ZA200407733B (en) 2005-10-26
DK1572087T3 (da) 2008-08-25
AU2003252830A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
TW200510459A (en) RG1 antibodies and uses thereof
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
EP1844077A4 (fr) Anticorps dr5 et utilisations de ceux-ci
IL214325A (en) Antibody against cmet, a drug that includes and uses it
IL244803B (en) Human anti-beta antibodies and their use
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
MX337052B (es) Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer.
GEP20074091B (en) Cripto blocking antibodies and uses thereof
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
TW200635946A (en) Binding proteins specific for human matriptase
WO2004067564A3 (fr) Compositions contre l'antgene cancereux liv-1 et leurs utilisations
WO2003072727A3 (fr) Anticorps monoclonaux specifiques d'egfrviii, ribozymes d'egfrviii et utilisations en detection, traitement ou prevention de cancer associe a l'egfrviii
WO2003076472A3 (fr) Anticorps specifiques des neoplasmes et leurs utilisations
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
WO2005094159A3 (fr) Methodes d'identification d'anticorps specifiques de tumeurs et utilisations
WO2004005351A3 (fr) Anticorps specifiques de neoplasme et utilisations associees
UY26170A1 (es) Antigeno (c42) asociados a tumores
WO2005048822A3 (fr) Anticorps et/ou conjugues associes se liant au fragment de terminaison amino de l'urokinase, leurs compositions et utilisations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed